Gene-Expression Profiling Suggests Impaired Signaling via the Interferon Pathway in Cstb(-/-) Microglia by Korber, Inken et al.
RESEARCH ARTICLE
Gene-Expression Profiling Suggests Impaired
Signaling via the Interferon Pathway in
Cstb-/- Microglia
Inken Körber1,2,3, Shintaro Katayama4, Elisabet Einarsdottir1,2,4, Kaarel Krjutškov4,5,
Paula Hakala1,2,3, Juha Kere1,2,4, Anna-Elina Lehesjoki1,2,3, Tarja Joensuu1,2,3*
1 Folkhälsan Institute of Genetics, Helsinki, Finland, 2 Research Program’s Unit, Molecular Neurology,
University of Helsinki, Helsinki, Finland, 3 Neuroscience Center, University of Helsinki, Helsinki, Finland,
4 Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden, 5 Competence Centre
on Health Technologies, Tartu, Estonia
* tarja.joensuu@helsinki.fi
Abstract
Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1, OMIM254800) is an
autosomal recessive neurodegenerative disorder characterized by stimulus-sensitive and
action-activated myoclonus, tonic-clonic epileptic seizures, and ataxia. Loss-of-function
mutations in the gene encoding the cysteine protease inhibitor cystatin B (CSTB) underlie
EPM1. The deficiency of CSTB in mice (Cstb-/-mice) generates a phenotype resembling
the symptoms of EPM1 patients and is accompanied by microglial activation at two weeks
of age and an upregulation of immune system-associated genes in the cerebellum at one
month of age. To shed light on molecular pathways and processes linked to CSTB defi-
ciency in microglia we characterized the transcriptome of cultured Cstb-/-mouse microglia
using microarray hybridization and RNA sequencing (RNA-seq). The gene expression pro-
files obtained with these two techniques were in good accordance and not polarized to
either pro- or anti-inflammatory status. InCstb-/-microglia, altogether 184 genes were differ-
entially expressed. Of these, 33 genes were identified by both methods. Several interferon-
regulated genes were weaker expressed in Cstb-/-microglia compared to control. This was
confirmed by quantitative real-time PCR of the transcripts Irf7 and Stat1. Subsequently, we
explored the biological context of CSTB deficiency in microglia more deeply by functional
enrichment and canonical pathway analysis. This uncovered a potential role for CSTB in
chemotaxis, antigen-presentation, and in immune- and defense response-associated pro-
cesses by altering JAK-STAT pathway signaling. These data support and expand the previ-
ously suggested involvement of inflammatory processes to the disease pathogenesis of
EPM1 and connect CSTB deficiency in microglia to altered expression of interferon-regu-
lated genes.
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Introduction
The neurodegenerative disease progressive myoclonus epilepsy of Unverricht-Lundborg type
(EPM1, OMIM254800) is an autosomal recessive disease with onset between 6 and 16 years of
age. It is characterized by progressive, stimulus-sensitive, and action-activated myoclonus,
which is resistant to medication and severely impairs patients’ everyday life [1]. In addition,
the patients have tonic-clonic epileptic seizures and develop ataxia. Loss-of-function mutations
in the cystatin B (CSTB) gene that encodes the cysteine protease inhibitor CSTB [2] underlie
EPM1. The mutations are associated with reduced CSTBmRNA as well as protein expression
[3, 4]. CSTB is a cytoplasmic protein, enriched around lysosomes, and in undifferentiated cells,
it has been detected also in nuclei [5]. The increased proteolytic activity of cathepsin B identi-
fied in CSTB-deficient cerebellar granule neurons and of cathepsin B, L, and S in EPM1 patient
lymphoblastoid cells implies that CSTB functions as a cathepsin inhibitior in vivo [6, 7]. CSTB
has been linked to the protection of neurons from apoptosis [8] and oxidative stress [6], as well
as regulation of cell cycle entry [9]. However, the underlying molecular mechanisms and how
the loss of CSTB causes the phenotype of EPM1 remain unknown.
The CSTB-deficient (Cstb-/-) mouse [8] is a widely used model to study EPM1 disease path-
ogenesis [10–14]. Its phenotype includes the characteristic symptoms of EPM1 patients: the
mice develop myoclonus by one month and progressive ataxia by six months of age [8]. Con-
sistent with findings in human patients [15–17], there is progressive atrophy, cortical thinning,
and neuron and white matter loss in the brain of Cstb-/- mice affecting particularly the cerebel-
lum and the thalamocortical system [8, 14, 16]. The earliest neuropathological finding in
Cstb-/- mice is the activation of microglia, the resident tissue macrophages of the CNS, at two
weeks of age. This is followed by the activation of astrocytes, myoclonus, and progressive neu-
ronal degeneration from one month onwards [14]. Gene-expression profiling has revealed an
upregulation of genes associated with immune-system processes in the cerebellum of Cstb-/-
mice at one month, and led to the discovery of alterations in GABAergic signaling already at
one week of age [18]. In detail, findings implying a diminished number of GABAergic pre- and
postsynaptic terminals, decreased inhibition, and reduced ligand binding to the α6-subunit-
containing GABAA receptors were identified in the cerebellum of Cstb
-/- mice [18].
Interestingly, the morphology of activated microglia in young Cstb-/- mice resembles that of
phagocytic brain macrophages and they develop thickened, branched processes at six months
of age [14]. Moreover, the activation of microglia in Cstb-/- mouse brain is dysfunctional, which
manifests as an imbalance between pro-inflammatory and anti-inflammatory microglial polar-
ization and as increased chemokine release and chemotactic activity, but possibly reduced anti-
gen presentation and phagocytic capacity [19]. In order to gain insight into the molecular
mechanisms underlying the abnormal microglial activation, we studied the transcriptional pro-
file of Cstb-/- mouse microglia. Our data link CSTB deficiency to downregulation of the inter-
feron-signaling pathway in microglia.
Materials and Methods
Ethics statement
The animal research protocols were approved by the Animal Ethics Committee of the State
Provincial Office of Southern Finland (decision no. STU376A, STH660A, and STH524A).
Mice
Cstb-/- mice were obtained from The Jackson Laboratory (Bar Harbor, ME; 129-Cstbtm1Rm/J;
stock no. 003486) [8]. Age-matched wild-type mice of the same background were used as
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controls. The mice were housed in the Center for laboratory animals at the University of Hel-
sinki with a 12 h / 12 h light-dark cycle and access to food and water ad libitum.
Primary microglial cultures
Cultures of mixed glia cells were extracted from postnatal day 5 (P5) mice as described earlier
[20] with slight modifications. Briefly, the P5 mice were euthanized carefully and without delay
by decapitation and after the removal of meninges, the cortices were triturated and incubated
with 20% trypsin (TrypLE Express, Life technologies, Carlsbad, CA) and 20 μg DNase (Roche
Diagnostics, Basel, Switzerland) for 20 min at 37°C, 5% CO2. Next, the cells were triturated 20
times, centrifuged (5 min at 1000 rpm), and, after resuspension, plated in fresh growth medium
(DMEM / 2 mM L-glutamine / 10% FCS / 1% penicillin-streptomycin) to 1% poly-D-lysine
(PDL) (Sigma-Aldrich, St. Louis, MO) coated T-75 tissue culture flasks. After shaking off the
primary microglia from the mixed glia cells at confluency (225 rpm, 37°C for 2.5 h), the cells
were re-plated and the growth medium was changed after 1 h at 37°C, 5% CO2 to fresh
medium containing 5 ng/ml mouse macrophage-colony stimulating factor (M-CSF, R&D Sys-
tems, Minneapolis, MN). The purity of microglial cultures was assessed by indirect immuno-
fluorescence with antibodies raised against the microglial marker F4/80 (AbD Serotec,
Hercules, CA) and the astrocytic marker glial fibrillary acidic protein (GFAP) (DakoCytoma-
tion, Santa Clara, CA).
RNA sample preparation for gene-expression profiling
Total RNA was extracted from cultured microglia of ten control and ten Cstb-/- mice using the
PerfectPure RNA Cultured Cell kit (5 PRIME, Hilden, Germany). For each sample (five control
and five Cstb-/- total RNA samples) the microglia cells of two mice of the same genotype were
pooled and the extracted RNA quality was controlled by chip-based capillary electrophoresis
(Bioanalyzer 2100, Agilent, Santa Clara, CA). All samples had an RNA integrity number (RIN)
> 7.5.
Transcriptome analysis by microarrays
Synthesis of cRNA from 100 ng total RNA per each of the five Cstb-/- and control microglial
samples and its hybridization to GeneChip Mouse Exon 1.0 ST arrays (Affymetrix Inc., Santa
Clara, CA, USA) were performed at the Helsinki Biomedicum Biochip Center (Finland). The
quality of each microarray was assessed by the Affymetrix GeneChip Operating Software
(GCOS) (Affymetrix Inc.) and the raw data were imported into GeneSpring GX software Ver-
sion 12 (Silicon Genetics, Incorporated, Redwood City, CA, USA) as an exon expression exper-
iment. The raw data were pre-processed by the RMA16 algorithm [21] considering only probes
with the highest confidence level (‘core’), which are based on Reference Sequence (RefSeq) and
full-length Genbank mRNAs as annotation sources. Probe summarization of the data was per-
formed by the RMA algorithm, which includes background correction, normalization, and
gene-level summarization. Shortly, the background was adjusted on a per-chip basis and the
normalization on probe level was performed by quantile normalization. The probe level data of
the perfect match (PM) values are summarized to exon-level probe sets and further to gene-
level transcript clusters, resulting in one expression value for each gene covered by the array.
Replicate samples of the same genotype were analysed in groups. Quality control on sample
level was performed by principal component analysis (PCA) and two arrays (one control and
one Cstb-/- array), which were outliers, were removed from downstream analysis. The expres-
sion values of the genes were filtered based on the summarized expression data; the lowest 20th
percentile of expression values was excluded from the analysis. For genes that had multiple
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entries in the gene list, only the list entry with the highest expression in control samples was
used for further analysis.
Expression values with an absolute fold change (FC) 1.3 between control and Cstb-/- were
considered differentially expressed. Statistical testing was done using T-test with unpaired
unequal variance corrected with Benjamini-Hochberg multiple testing correction and an
adjusted p-value< 0.05 was considered significant. The microarray gene expression data are
accessible in the Gene Expression Omnibus (GEO, NCBI, www.ncbi.nlm.nih.gov/geo/) reposi-
tory (ID: GSE64823).
Transcriptome analysis by RNA-seq
Bulk-RNA transcriptome analysis of four technical replicates per each of the five Cstb-/- and
control microglial RNA samples was performed by the RNA-seq method, followed by the sin-
gle-cell tagged reverse transcription (STRT) [22] protocol with modifications [23]. 10 ng of
total RNA was converted to cDNA and amplified to form an Illumina-compatible library. Arti-
ficial ERCC RNA Spike-In Mix 1 (Life Technologies, USA) was diluted to 1:1000 and 1 μl was
used to enable data normalization. In total, 25 PCR cycles were used, but as four base-pair
unique molecular identifiers were applied, only the absolute number of unique reads was calcu-
lated per analysed sample. The library was sequenced on one lane of Illumina HiSeq2000, fur-
ther processed to fastq files by Casava 1.8.2 (both Illumina, San Diego, CA, USA), and quality
control was performed using the STRTprep pipeline (https://github.com/shka/STRTprep)
[23]. Briefly, the filtered sequence reads were aligned to the mouse UCSC genome mm9 [24],
the mouse ribosomal DNA repetitive unit (GenBank: BK000964), the E. coli ynbA (GenBank:
EF011072 as negative control), and the ERCC spike-in RNAs by TopHat [25] with UCSC
Known Genes (version from 23.06.15) [26] as transcriptome reference. In the data analysis, we
excluded the same two RNA samples (one Cstb-/- and one control sample) that were excluded
in the microarray analysis. The raw read frequencies are counts of the STRT reads, which
aligned within the 5’-UTR or up to 500 bp upstream of each protein-coding gene in the sample.
The normalized expression level is the raw read frequency divided by total read counts, which
aligned to the ERCC spike-ins in the sample, as spike-in normalization. From all identified
genes, a gene was considered expressed if more than two of the normalized expression values
from all the technical repeats of the control and Cstb-/- samples were greater than zero. The
genes differentially expressed between control and Cstb-/- RNA samples were identified by
SAMstrt, with spike-in based normalization [27] and by their degree of fluctuation or variation
[23]. We considered genes with a FDR q-value< 0.01 and a significant fluctuation (adjusted p-
value< 0.01) as differentially expressed between control and Cstb-/- samples.
Platform comparison
The platform comparison was performed between the expression data obtained by microarray
and RNA-seq approach. The microarray gene expression values summarized by RMA16 were
filtered for protein-coding genes using the current, protein-coding mouse (taxon ID: 10090)
genes from NCBI Gene (version from 13.11.15) [28] and were compared to the normalized
gene expression values obtained by RNA-seq. Correlation was determined by Spearman’s rank
correlation coefficient.
Functional annotation of the transcriptome
Gene ontology (GO) terms enriched in the differentially expressed genes in Cstb-/- microglia
were identified using the web-based gene ontology enrichment analysis and visualization tool
GOrilla (www.cbl-gorilla.cs.technicon.ac.il, version from 22.07.2015) [29, 30]. A p-value
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threshold of 0.001 was considered significant. Canonical pathways and upstream regulators
enriched in the differentially expressed genes were identified using QIAGEN´s Ingenuity Path-
way Analysis (IPA, QIAGEN, Redwood City, US, www.qiagen.com/ingenuity, version from
22.07.15) in a Core analysis using the Fisher´s Exact test and a p-value< 0.05 cutoff. In the
core analysis, identified upstream regulators were ranked by a z-score, which reflected the
probability that the regulator underlay the observed expression changes. The protein network
was generated with the protein-protein interaction database Search Tool for the Retrieval of
Interacting Genes/Proteins (STRING) 10 (www.string-db.org, version from 18.09.2015) [31]
and illustrated with Cytoscape 3.2 [32].
Quantitative real-time PCR (qPCR)
Isolation of total RNA from cultured control and Cstb-/- mouse microglia was performed using
the RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.
For each sample, the RNA of 2–4 mice per genotype was pooled. The concentration and purity
of the RNA was assessed spectrophotometrically (ND-1000, NanoDrop Technologies, Wil-
mington, DE) and RNA was transcribed to cDNA using the iScript cDNA Synthesis Kit (Bio-
Rad Laboratories, Hercules, CA) according to the manufacturer’s instructions. Absence of
genomic DNA in the RNA samples was determined by amplification of the ribosomal protein
S15 by PCR. TaqMan Gene Expression assays (Applied Biosystems, Foster City, CA) were
used for quantitative real-time PCR (qPCR), which was performed on an ABI Prism 7000
Sequence Detection System according to the manufacturer’s instructions. These TaqMan
Gene Expression Assays were used:mStat1 (Mm00439531_m1),mIrf7 (Mm00516793_g1),
mIrf9 (Mm00492679_m1), andmTbp (Mm00446973_m1). DataAssist software Version 3.01
(Applied Biosystems) was used to perform relative quantification of the data using the compar-
ative Ct (ddCt) method [33]. The Tata-binding protein (Tbp) transcript expression was used as
endogenous control and statistical tests were performed using GraphPad Prism version 6.02
for Windows (GraphPad Software, La Jolla, California, USA, www.graphpad.com). Statistical
significance between control and Cstb-/- samples was determined using the unpaired t-test with
Welch’s correction and a significance level of p< 0.05 was considered statistically significant.
JAK-STAT signaling pathway PCR assay
Total RNA was extracted from primary cultured microglia cells from control and Cstb-/- mice
using the RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instruc-
tions. For each sample, the RNA of 3 mice per genotype was pooled. RNA concentration and
purity was determined spectrophotometrically (ND-1000) and the mouse JAK/STAT Signaling
Pathway RT2 Profiler PCR Array (Qiagen) was performed according to the manufacturer’s
instructions using the ABI Prism 7000 Sequence Detection System (Applied Biosystems).
Results
The majority of differentially expressed genes in Cstb-/-microglia are
downregulated
To generate a comprehensive transcript profile of CSTB-deficient microglia, we assessed gene
expression changes between Cstb-/- and control microglia with two different expression profil-
ing methods, microarray analysis and RNA-seq.
First, we analyzed the microglia RNA samples by microarray using the Affymetrix Mouse
Exon 1.0 ST arrays and identified 14 147 expressed transcript clusters. To pinpoint the relevant
expression changes in Cstb-/- microglia, we then focused on the transcript clusters with an
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absolute FC of at least 1.3 and a corrected p< 0.05, and detected 155 differentially expressed
genes (DEGs; S1 Table). Of these, only four genes were upregulated (FC range: 1.3 to 1.8; high-
est FC: lysophosphatidylcholine acetyltransferase 4 (Lpcat4)), and the majority, 151 genes,
were downregulated (FC range: -9.3 to -1.3). The downregulated genes included several inter-
feron-regulated genes, such as interferon-induced protein with tetratricopeptide repeats 1
(Ifit1, FC: -8.1), 2’-5’ oligoadenylate synthetase-like 2 (Oasl2, FC: -6.6), and interferon regula-
tory factor 7 (Irf7, FC: -5.3).
Second, we performed RNA-seq of the microglia RNA samples using the single-cell tagged
reverse transcription (STRT) protocol [22]. After removal of redundant reads, which are gener-
ated during PCR amplification, we obtained on average 2 129 122 (± 7.1%) total reads per sam-
ple sequenced on one Illumina HiSeq2000 lane. Of these total reads, 1 884 590 (± 7%) per
sample were mapped to the genome (mapped rate), 1 654 282 (± 7.1%) per sample were
mapped to coding sequence and 1 337 991 (± 7.5%) per sample were mapped to coding 5’
regions (S2 Table). In this analysis, we detected 11 222 genes with altered expression in Cstb-/-
microglia based on the variation in the number of sequence reads obtained from added RNA
spike-ins by SAMstrt [27], which has been utilized to assess differential expression previously
[34, 35]. To focus on the significant differences, we considered only genes with a false discovery
rate (FDR)< 0.01 and a significant fluctuation (adjusted p-value< 0.01), and 62 genes passed
this criteria (S1 Table). Of these, four genes were upregulated (FC range: 1.8 to 4.8; highest FC:
serine peptidase inhibitor, clade B, member 10 (Serpinb10-ps)), and 58 genes were downregu-
lated (FC range: -200 to -2.2). Among the most downregulated genes, a few were interferon-
regulated genes, e.g. Oasl2 (FC: -17.9), ISG15 ubiquitin-like modifier (Isg15) (FC: -11.9), Ifit3
(FC: -11.8), and Ifit1 (FC: -11.2).
Microarray and RNA-seq results are concordant
To investigate the Cstb-/- microglia transcriptome, we examined the expression data in more
detail. In this analysis, we restricted the genes detected by microarray to protein-coding genes,
because the standard procedure of STRTprep for differential expression and pathway analysis
specifically targets protein-coding genes.
Overall, the total transcription profiling of Cstb-/-microglia provided expression data of 14
420 genes. Of these, 2 844 (20%) were identified only by RNA-seq, 3 198 (22%) were uniquely
identified by microarray, and 8 378 (58%) were detected by both techniques (Fig 1A). Interest-
ingly, genes that were identified to be differentially expressed only by one of the methods showed
weaker expression than genes identified by both techniques (Fig 1B–1E). To explore the consis-
tency between the microarray and the RNA-seq data, we determined the accordance between
gene expression values, and found a moderate correlation both in control (Spearman´s rank cor-
relation coefficient, SCC: 0.47) and in Cstb-/-microglia (SCC: 0.45) (Fig 1F and 1G). To evaluate
this further, we investigated, as a measure less dependent on the normalization method, also the
correlation between the fold changes obtained by microarray and by RNA-seq (SCC: 0.51),
which was comparable to the correlation between expression values.
Altogether, 184 genes are differentially expressed in Cstb-/- microglia (S1 Table). We
observed good accordance in DEGs identified by both methods, which was expected as the
number of polyadenylated transcripts in control and Cstb-/- RNA samples was similar (589 and
598 for 10 ng RNA, respectively). In addition, we observed good correlation between the fold
changes of these genes (SCC: 0.73) (Fig 2A). Only six DEGs (3.2%) had different fold change
directions. They were altered only in the microarray-based data, and were therefore probably
false positive discoveries. Of the 184 DEGs in Cstb-/- microglia, 33 (18%) genes were shared by
both methods (marked with an asterisk () in S1 Table) (Fig 2B). Although their number was
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Fig 1. Gene expression values identified bymicroarray- and sequencing-based transcriptome profiling ofCstb-/-microglia. (A) Venn
diagram illustrating the overlap in the number of genes identified by both methods (blue), only by microarray (green), or only by RNA-seq (red). (B–
E) Distribution of microarray and RNA-seq gene expression values in control andCstb-/-microglia. The expression values of genes identified also
in the other method (blue bars) are higher than the expression values identified only by the microarray or the RNA-seq (grey bars). The number of
genes with a specific gene expression value is depicted for (B) control and (C) Cstb-/-microglia in the microarray and for (D) control and (E)Cstb-/-
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Fig 2. DEGs identified by microarray- and sequencing-based expression profiling of Cstb-/-microglia. (A) Scatter plot of the FCs
of the differentially expressed genes (DEGs) identified by microarray and RNA-seq. DEGs common to both methods are depicted in
orange, RNA-seq-specific DEGs in light blue, and microarray-specific DEGs in purple. (B) Venn diagram showing the overlap in the
number of DEGs. The colors correspond to the colors in A. (C) Protein-protein interaction network of the 33 genes differentially
expressed in microarray and RNA-seq. The size of each node is proportional to the number of its connections to other nodes and the
color of each node illustrates the fold change of the gene it represents.
doi:10.1371/journal.pone.0158195.g002
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small, the overlap was significantly higher than expected (odds ratio = 132.2, p< 2.2e-16 by
Fisher’s Exact test for Count Data, S3 Table), and their gene expression levels were not lower
than the levels of the non-overlapping DEGs (S1 Fig). They showed good accordance in their
fold changes (SCC: 0.75) and formed a highly interconnected network (Fig 2C), in which for
example Irf7, Ifit1, Oasl2, and Stat1 had central positions. In addition, 122 DEGs were altered
uniquely in the microarray profiling. Of these, 98 (80%) were identified, but not altered, in the
RNA-seq profiling. Moreover, 29 genes were changed only in the RNA-seq data and of these
13 (45%) were detected, but not altered, in the microarray profiling.
In summary, the analysis demonstrated good concordance between both technologies and
provided a detailed and solid signature of CSTB deficiency in microglia.
RNA expression profiles indicate that microglia are neither pro- nor anti-
inflammatory polarized
In order to assess howmicroglia-specific the transcription profiles of the control and Cstb-/- sam-
ples were compared to known microglial transcript expression profiles, we extracted from the
microarray and the RNA-seq data the expression values of 100 genes that have been reported to
be highly expressed in microglia [36]. In control and Cstb-/-microglia, 81 of these genes were
detected by microarray (Fig 3A) and 93 by RNA-seq profiling (S2A Fig). Of these genes, Fc
gamma receptor 1 (Fcgr1), lectin, galactose binding, soluble 9 (Lgals9), CD86 antigen (Cd86),
CD22 antigen (Cd22), and chemokine (C-C-motif) receptor-like 2 (Ccrl2) were downregulated in
Cstb-/-microglia in the microarray data (marked with an asterisk in Fig 3A) and C-type lectin
domain family 4, member a3 (Clec4a3) in the RNA-seq data (marked with an asterisk in S2A Fig).
In general, microglia are very sensitive to disturbances, and react with morphological and
gene expression changes to alterations in their environment. We therefore also evaluated the
expression of markers for activation of control and Cstb-/- microglia in the microarray and
RNA-seq data. To achieve this, we focused on the expression levels of transcripts previously
associated with pro-inflammatory or anti-inflammatory microglial polarization [37]. In control
and Cstb-/- microglia, genes linked to pro- and anti-inflammatory function were expressed, but
the microglia were not polarized to either state (Fig 3B and 3C). The expression of only four
pro-inflammatory genes, namely Cd86, Interleukin 1β (Il1b), and chemokine (C-C motif)
ligand 5 (Ccl5) and chemokine (C-X-C motif) ligand 10 (Cxcl10), was significantly altered
between Cstb-/- and control microglia (marked with an asterisk in Fig 2B) in the microarray
and Ccl5 and Cxcl13 in the RNA-seq data (marked with an asterisk () in S2B and S2C Fig).
In conclusion, these data suggest that CSTB deficiency did not substantially alter the expres-
sion of genes that were considered central for the transcriptional signature defining microglia
cells or for the regulation of microglial activation.
Functional enrichment analysis indicates impaired immune-system
related functions in Cstb-/-microglia
To explore more deeply the biological context of the DEGs in Cstb-/- microglia, we determined
their associated biological processes, molecular functions, and cellular locations using Gene
Ontology (GO) enrichment analysis, which we performed separately for the microarray (S4
Table) and the RNA-seq data (S5 Table).
The most significantly enriched biological processes in Cstb-/- microglia in both analyses
included GO terms associated with immune and defense response, as well as interferon (INF)
signaling. In addition, the Cstb-/- microglia DEGs were implicated in processing and presenta-
tion of antigens. This category comprised genes that are involved in generation of antigenic
peptides in the proteasome (proteasome subunit beta type-9 (Psmb9)) and in peptide
Gene-Expression Profiling inCstb-/-Microglia
PLOS ONE | DOI:10.1371/journal.pone.0158195 June 29, 2016 9 / 19
translocation from cytoplasm into the endoplasmic reticulum (transporter 1, ATP-binding cas-
sette, sub-family B (MDR/TAP) (Tap1) and Tap binding protein (Tapbp)). Furthermore, we
identified GO terms linked to migration and chemotaxis exclusively in the RNA-seq results.
Fig 3. Microarray expression values of genes associated with microglia or microglial activation in control andCstb-/-microglia.Microarray gene
expression level of transcripts (A) reportedly enriched in microglia, (B) associated with pro-inflammatory, and (C) with anti-inflammatory activation of
microglia determined in control (black bars) andCstb-/- (grey bars) microglia. The asterisk (*) marks genes significantly altered in Cstb-/-microglia
compared to control microglia. Error bars represent standard deviation (SD).
doi:10.1371/journal.pone.0158195.g003
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This category included e.g. the cytokines Cxcl3, Il16, and Ccl2, as well as the complement recep-
tors integrin alpha M (Itgam) and complement component 5a receptor 1 (C5ar1).
Themolecular functions enriched in Cstb-/- microglia included nucleotide binding, GTPase
activity as well as chemotaxis. The microarray DEGs were involved in nucleotide binding,
which comprised several oligoadenylate synthases (Oas) (Oas1a/g, Oas1b, and Oas2) that syn-
thesize 2´-5´-linked oligoadenylates in an ATP-dependent manner, as well as the OAS-like
proteins 1 and 2 (Oasl1, Oasl2). In addition, this category contained genes encoding schlafen
(SLFN) proteins (Slfn2, Slfn5, Slfn8/9) and several helicases (DEXH box polypeptide 58
(Dhx58), activating signal cointegrator 1 complex subunit 3 (Ascc3), DEAD box polypeptide 58
(Ddx58), interferon induced with helicase C domain 1 (Ifih1), and Moloney leukemia virus 10
(Mov10)). The genes possessing GTPase activity were interferon-inducible GTPases. This cate-
gory included genes such as Mx dynamin-like GTPase 1 (Mx1),Mx2, guanylate binding pro-
tein 2/1 (Gbp2/1), Gbp6/3, immunity-related GTPase family M member 1 (Irgm1), Irgm2, and
very large interferon inducible GTPase 1 (Gvin1). The RNA-seq-based molecular functions
highlighted the association of CSTB deficiency with chemotaxis, including genes such as Ccl2,
Cxcl13, Cxcl2, Cxcl3, and Cxcl10.
The GO terms describing cellular components in Cstb-/- microglia were associated with cell
membranes and the extracellular space in both methods.
Interferon signaling pathway is downregulated in Cstb-/-microglia
Next, we asked whether the DEGs shared common regulators potentially mediating the gene
expression changes in Cstb-/- microglia and if these genes were part of the same biological path-
way. Therefore, we examined the microarray and the RNA-seq findings for molecular path-
ways (Fig 4, detailed results in S6 Table) and potential upstream regulators (Fig 5, detailed
results in S7 Table) linked to CSTB deficiency in microglia.
The molecular pathways over-represented in Cstb-/- microglia in both methods were
involved in regulation of the innate immune system and interferon signaling (Fig 4). They
included for example the recognition of pathogens and cellular damage by pattern recognition
receptors (PRRs), the activation of interferon-regulated factors (IRFs), and signaling via the
interferon pathway. The upstream regulators enriched in Cstb-/- microglia comprised the mito-
chondrial antiviral signaling protein (MAVS), the transcription factors IRF7, IRF3, and Signal
transducer and activator of transcription 1 (STAT1), as well as several interferons (IFNλ1,
IFNα2, IFNβ1, and IFNγ), and the interferon-α/β receptor (INFαR) (Fig 5). The majority of
these regulators act either upstream of the JAK-STAT signaling pathway or control the signal
transduction of this pathway [38], suggesting that it might mediate the altered expression of
interferon regulated genes in Cstb-/- microglia.
To further investigate this, we performed qPCR of interferon-pathway regulators Irf7, Irf9,
and the transcription factor Stat1 and a qPCR-based JAK-STAT pathway assay from control
and Cstb-/- microglia RNA samples. The qPCR confirmed the downregulation of Irf7 and Stat1
(S3 Fig). However, expression of the interferon-regulated gene Irf9, which was only slightly
downregulated on the microarray (FC: -1.6), was reduced, but did not reach statistical signifi-
cance. The JAK-STAT pathway assay, which determines transcript levels of 84 genes previously
associated with this pathway, revealed only modest gene expression changes in Cstb-/- micro-
glia. We utilized a FC cut off of 1.3 and identified four downregulated genes (FC range: -1.3 to
-1.5) and 40 upregulated genes (FC: 1.3 to 2.5) (Table 1). Using this assay, we were able to pin-
point the downregulation of Irf9.
In summary, our results showed a reduced expression of interferon-regulated genes in
Cstb-/- microglia and implied a putative role for CSTB in regulation of interferon signaling.
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Fig 4. Canonical pathways enriched inCstb-/-microglia identified by microarray and RNA-seq
analyses. The 14 canonical pathways most highly ranked based on their p-value in the microarray (black
color) and the RNA-seq approach (grey color) are depicted. The p-values and the fold changes of the
microglia genes linked to each pathway are illustrated for both methods results.
doi:10.1371/journal.pone.0158195.g004
Fig 5. Upstream regulators enriched inCstb-/-microglia identified bymicroarray and RNA-seq analyses. The 12
upstream regulators most highly ranked based on their p-value in the microarray (black color) and the RNA-seq approach
(grey color) are depicted. The z-scores and the fold changes of all genes potentially controlled by this regulator are
illustrated for both methods.
doi:10.1371/journal.pone.0158195.g005
Gene-Expression Profiling inCstb-/-Microglia
PLOS ONE | DOI:10.1371/journal.pone.0158195 June 29, 2016 12 / 19
Discussion
Our previous findings of an early activation and dysfunction of Cstb-/- microglia with conse-
quent neuroinflammation [14, 19] and an upregulation of genes linked to immune system pro-
cesses in cerebella of one-month-old Cstb-/- mice [18] strongly supported a contribution of
microglial dysfunction and inflammatory processes in the pathogenesis of EPM1. To scrutinize
especially the microglial dysfunction associated with CSTB deficiency in more depth, we here
focused on global gene expression profiling of cultured Cstb-/- and control microglia by apply-
ing a combination of two widely used gene expression profiling methods, microarray and
RNA-seq, to the same RNA samples. Transcriptome profiling is a useful method to pinpoint
altered cellular pathways. For example in neural stem cells, Notch signaling has been shown to
be regulated by sirtuin 1(SIRT1) using this technique [39]. In Cstb-/- mice, we have successfully
utilized this method previously and found altered expression of synaptic genes in the cerebel-
lum, which led to the finding of reduced GABAergic inhibition of Cstb-/- cerebellar Purkinje
cells [18]. Our comparison of the Cstb-/- microglia microarray and RNA-seq results revealed
good concordance between both techniques, which was expected due to the similarities in the
amounts of polyadenylated transcripts in Cstb-/- and control samples. For example, more than
half of all identified genes were detected by both methods, and their gene expression values as
well as fold changes correlated reasonably well. The correlation in gene expression values was
slightly less strong, but comparable with earlier reports comparing RNA-seq and microarrays
[40–42]. Moreover, we found good concordance between the functional enrichment analyses,
although the number of DEGs shared by both methods was small. This might be due to the dif-
ferent normalization methods used in both studies. The RNA-seq data are normalized to
spike-in RNAs with known sequence and concentration that are added to the samples and the
microarray data are normalized between arrays by quantile normalization, although Gene-
Chips can also be normalized by spike-in RNAs, e.g. [43]. In addition, the probe selection on
the microarray might underlie the differences. The microarray probes are spread over different
exons in the genes, whereas the STRT RNA-seq protocol only counts mapped reads within the
Table 1. JAK-STAT pathway-associated transcripts differentially expressed inCstb-/-microglia.
Gene Symbol FC Gene Symbol FC Gene Symbol FC
Irf9 -1.5 Il20 1.5 Socs5 1.7
Smad2 -1.4 Nr3c1 1.5 Jak3 1.7
Sp1 -1.4 Il10rb 1.5 Myc 1.7
Csf1r -1.3 Il4 1.5 Cxcl9 1.7
Il10ra 1.3 Fcer2a 1.5 F2 1.8
Sh2b2 1.3 Junb 1.5 Lrg1 1.8
Pdgfra 1.3 Il4ra 1.5 Nos2 1.8
Pias1 1.3 Ifng 1.5 Socs2 1.9
Ifngr1 1.3 Hmga1 1.6 Prl 2.0
Ptpn1 1.3 Osm 1.6 Jun 2.1
Socs3 1.4 A2m 1.6 Mpl (TPO-R) 2.1
Crp 1.4 Stat5a 1.6 Epor 2.1
Bcl2l1 1.4 Tyk2 1.6 Gata3 2.4
Socs1 1.4 Ghr 1.6 Stat4 2.5
Smad4 1.5 Src 1.7
Relative gene expression levels were determined by JAK-STAT pathway array and the fold change (FC) between control and Cstb-/-microglia was
calculated. All genes with an absolute FC 1.3 are considered differentially expressed.
doi:10.1371/journal.pone.0158195.t001
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5’-UTR or up to 500 bp upstream of known protein-coding genes. Moreover, the STRT RNA-
seq detects only intact mRNAs, which are used as templates for protein translation, but it is not
ideal for the detection of some longer mRNAs, because it uses oligo-dT primer for the first-
strand cDNA synthesis. In contrast, the microarray uses random primer and therefore mea-
sures degrading mRNAs as well, but it is better for long mRNAs. Sequencing depth for the
RNA-seq analysis is another factor, the optimal sequencing depth depends on the aim of the
study and on the transcriptome complexity of the target sample. In addition, the amount of
input RNA influences the detection power. In this first STRT study, we used 10 ng total RNA
for each replica (equivalent to 40 ng for each sample; while 100 ng for the microarray), and
sequenced one STRT library containing all replicas of all samples on one HiSeq2000 lane.
Although this setup identified dominant gene expression changes, which were also detected by
microarray, a much deeper sequencing might also reveal more subtle expression changes [44].
Although there were many possibilities, one consistent result was that in both approaches the
majority of genes showing significantly altered expression in Cstb-/- microglia were
downregulated.
The adult mouse microglia transcriptome has been determined by RNA-seq [36] and the
100 genes with highest expression were linked to the detection of molecules, such as pattern
recognition receptors, and purinergic receptors, and thus have been called the microglial ‘sen-
some’. The evaluation of the sensome gene expression in Cstb-/- and control microglia revealed
that the majority of these genes are also expressed in primary microglia, although both studies
differed in extraction and culturing of the cells. In addition, the expression of microglial sen-
some genes was not altered considerably in Cstb-/- microglia compared to control microglia. To
characterize not only the sensome of Cstb-/- microglia, but also their activation, the expression
of pro- and anti-inflammatory phenotypic markers can be analyzed [37]. Our previous study
showed that in Cstb-/- mice, the balance between pro-inflammatory and anti-inflammatory
activated microglia was, compared to controls, shifted towards anti-inflammatory type at P14
and towards pro-inflammatory type in P30. We also described upregulated protein expression
of both the pro-inflammatory marker iNOS and the anti-inflammatory marker Arginase1 in
P30 Cstb-/- mouse brain [19]. However, the primary cultured Cstb-/- microglia in this study
were neither pro- nor anti-inflammatory activated in vitro. We noted a down-regulation of five
pro-inflammatory genes (Cd86, Il1b, Ccl5, Cxcl10, Cxcl13), which, however, might be due to
the altered interferon signaling, because most of these genes were interferon regulated accord-
ing to the database Interferome 2.0 [45].
The GO enrichment analysis indicated that CSTB deficiency in microglia altered immune
system- and defense response-related functions. More specifically, GO terms associated with
antigen presentation and chemotaxis were over-represented in Cstb-/- microglia. These data are
in line with previous in vitro studies in Cstb-/- microglia and bone marrow-derived macro-
phages (BMDM), which have shown altered immune cell functions, suggesting e.g. changes in
antigen presentation and chemotaxis [11, 19, 46]. Further analyses of the altered pathways and
their upstream regulators indicated that the mechanism underlying the dysfunction of Cstb-/-
microglia might be associated with interferon signaling and the JAK-STAT pathway. Interferon
signaling is an important regulator of the innate immune response mediating the defense
against viral infections [38]. However, in recent years also other functions for interferon signal-
ing have been emerging, e.g. the regulation of autophagy [47]. Both enhanced and impaired
interferon signaling has been linked to pathological conditions [48]. For example, enhanced
IFN signaling has been associated with autoimmune diseases, such as rheumatoid arthritis and
systemic lupus erythematosus [49]. In contrast, IFNβ-mediated signaling ameliorated pathol-
ogy in ischemic stroke and cerebral ischemia [50, 51], suggesting a beneficial role for interferon
signaling. Moreover, STAT1 and IRF9 are protective against neuropathology mediated by
Gene-Expression Profiling inCstb-/-Microglia
PLOS ONE | DOI:10.1371/journal.pone.0158195 June 29, 2016 14 / 19
chronic astrocytic IFNα expression, which induces e.g. neurodegeneration, inflammation, and
glial activation [52, 53]. Our results indicating altered interferon regulated JAK-STAT signaling
in microglia are in line with previous studies analyzing Cstb-/- BMDMs of adult mice. These
showed reduced activation or expression of proteins on this pathway in response to pro-
inflammatory stimulation, e.g. reduced STAT1 activation by tyrosine phosphorylation and
Ifnb1mRNA expression [11, 46]. In Cstb-/- microglia, Stat1mRNA abundance was reduced,
however, Ifnb1 expression was not altered, which might be due to a cell type specific downregu-
lation of Ifnb1 in Cstb-/- BMDMs. In addition, we might not be able to detect the downregula-
tion of Ifnb1, because of its weak constitutive expression level [54].
Reduced signaling via the interferon pathway in Cstb-/- microglia might also have implica-
tions for other cellular processes. For example, IFNβ-induced IFNAR signaling inhibits reactive
oxygen species production and inflammasome activation [55]. Thus, reduced IFN signaling in
Cstb-/- mice might elevate inflammasome activation and induce the activation of the pro-
inflammatory cytokines IL1β and IL18, which have been shown at high levels in the serum of
LPS-injected Cstb-/- mice [11] and have been linked to the pathogenesis of several neurodegen-
erative diseases, such as Alzheimer’s disease and multiple sclerosis [56]. We observed a
decreased Il1bmRNA expression in Cstb-/- microglia, however, the microglia samples in our
study were not pro-inflammatory activated.
In addition to affecting the immunological functions, altered interferon signaling in Cstb-/-
immune cells might have a more direct impact on neuronal signaling and/or viability. For
example, IFNγ has been reported to suppress the differentiation of GABAergic neurons from
neuronal progenitor cells, and to induce the generation of glutamatergic neurons [57].
Although we were not able to pinpoint altered Ifng expression in Cstb-/- microglia, it is, in light
of our previous electrophysiological recordings of P7 Cstb-/- Purkinje cells, which have revealed
an imbalance between excitation and inhibition in Cstb-/- mouse brain [18], tempting to specu-
late that impaired interferon signaling in Cstb-/-microglia could modify the excitability and via-
bility of Cstb-/- neurons.
Conclusion
Collectively, the integration of data from microarray and RNA-seq technologies strengthened
and expanded the previously reported indications of impaired interferon-signaling pathway in
Cstb-/- mice to a general downregulation of interferon-regulated genes [11, 46]. Moreover, our
results supported previous findings suggesting that modified inflammatory processes of micro-
glia contribute to the pathogenesis of EPM1.
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